Back to Results
Jonas B. Galper, MD, PhD
Director, Laboratory of Lipid Metabolism and CardioVascular Signaling, Molecular Cardiology Research Institute; Professor, Tufts University School of Medicine
Department + Services
Medicine, CardioVascular Center, Cardiology
General cardiology, molecular mechanisms of cardiovascular diseases
Seeing Patients In
|Programs + Specialties
|Training + Education
Albert Einstein College of Medicine; Tufts Medical Center; National Institutes of Health; Brigham and Women's Hospital
Tufts Medical Center
South Building, 6th Floor
800 Washington St.
Boston, MA 02111
Fax #: 617-636-4833
Phone #: 617-636-2273
1. Park HJ, Georgescu SP, Du C, Madias C, Aronovitz MJ, Welzig CM, Wang B, Begley U, Zhang Y, Blaustein RO, Patten RD, Karas RH, Van Tol HH, Osborne TF, Shimano H, Liao R, Link MS, Galper JB. Parasympathetic response in chick myocytes and mouse heart is controlled by SREBP. Journal of Clinical Investigation 2008;118(1):259-271.
2. Park HJ, Zhang Y, Georgescu SP, Johnson KL, Kong D, Galper JB. Human umbilical vein endothelial cells and human dermal microvascular endothelial cells offer new insights into the relationship between lipid metabolism and angiogenesis. Stem Cell Reviews 2006;2(2):93-102.
3. Park HJ, Ward SM, Desgrosellier JS, Georgescu SP, Papageorge AG, Zhuang X, Barnett JV, Galper JB. Transforming growth factor β regulates the expression of the M² muscarinic receptor in atrial myocytes via an effect on RhoA and p190RhoGAP. Journal of Biological Chemistry 2006;281(29):19995-20002.
4. Tang D, Park HJ, Georgescu SP, Sebti SM, Hamilton AD, Galper JB. Simvastatin potentiates tumor necrosis factor ∝-mediated apoptosis of human vascular endothelial cells via the inhibition of the geranylgeranylation of RhoA. Life Sciences 2006;79(15):1484-1492.
5. Welzig Cm, Shin D-G, Park H-J, Kin Y-J, Saul JP, Galper JB. Lipid Loweringby Pravastatin Increases Parasympathetic Modulation of Heart Rate: Gi2 as a Possible Molecular Marker of Parasympathetic Responsiveness. Circulation. 2003;108: 2743-2746, 2003.
6. Park H-J, Kong D, Iruela-Arispe L, Begley U, Tang D, Galper JB. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA. Circ. Res. 2002;91:143-150.
7. Park, H-J, Begley U, Kong D, Yu H, Yin L, Hillgartner FB, Osborne TF, Galper JB. Role of sterol regulatory element binding proteins in the regulation of Galphai2 expression in cultured atrial cells. Circ. Res. 2002;91:32-37.
8. Gadbut AP, Wu L, Tang, D, Papageorge A, Watson, JA, Galper JB. Low density lipoproteins regulate levels of functional RAS in embryonic chick heart cells: A role for RAS in regulating the expression of muscarinic receptors and G-proteins. The Embo J 1997;16;7250-7260.
9. Haigh LS, Leatherman GF, O'Hara DS, Smith TW, Galper JB. Effects of low density lipoproteins and mevinolin on cholesterol content and muscarinic responsiveness in cultured chick atrial cells: Regulation of levels of muscarinic receptors and guanine nucleotide regulatory proteins. J Biol Chem 1988; 263:15608-15618.
Dr. Galper received his BA in chemistry from Harvard College. He received his MD and PhD from the Albert Einstein College of Medicine and did his house staff training at New England Medical Center (now Tufts Medical Center). He served as a Clinical Associate at the National Heart Lung and Blood Institute at the National Institutes of Health. He received his fellowship training in Cardiology at the Peter Bent Brigham Hospital and became a faculty member at the Harvard Medical School and attending physician at the Brigham and Women’s Hospital as an instructor, assistant professor and associate professor. He is an Established Investigator of the American Heart Association and has served on the editorial boards of Circulation Research and the Journal of Molecular and Cellular Cardiology. Dr. Galper has a program for the study of the role of lipids in signaling in the cardiovascular system and is involved in collaborations with Drs. Richard Karas and Mark Estes.